M
11.96
-0.18 (-1.48%)
Penutupan Terdahulu | 12.14 |
Buka | 11.97 |
Jumlah Dagangan | 198,090 |
Purata Dagangan (3B) | 285,435 |
Modal Pasaran | 523,572,928 |
Harga / Jualan (P/S) | 2.88 |
Julat 52 Minggu |
Margin Keuntungan | 32.97% |
Margin Operasi (TTM) | -969.16% |
EPS Cair (TTM) | -0.420 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 79.66% |
Nisbah Semasa (MRQ) | 8.77 |
Aliran Tunai Operasi (OCF TTM) | 77.76 M |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | Maze Therapeutics, Inc. | Menurun | - |
AISkor Stockmoo
0.8
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | -0.5 |
Purata | 0.75 |
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 11.49% |
% Dimiliki oleh Institusi | 56.93% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 30.00 (JP Morgan, 150.84%) | Beli |
Median | 28.00 (134.11%) | |
Rendah | 19.00 (Guggenheim, 58.86%) | Beli |
Purata | 25.67 (114.63%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 10.41 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Guggenheim | 02 Apr 2025 | 19.00 (58.86%) | Beli | 10.09 |
25 Feb 2025 | 19.00 (58.86%) | Beli | 10.57 | |
JP Morgan | 25 Feb 2025 | 30.00 (150.84%) | Beli | 10.57 |
Leerink Partners | 25 Feb 2025 | 28.00 (134.11%) | Beli | 10.57 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
31 Mar 2025 | Pengumuman | Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights |
07 Feb 2025 | Pengumuman | Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |